Conestoga Capital Advisors, LLC on Repligen Corporation
Thesis
Repligen supplies products and technologies for biologic drug production, making it sensitive to the recovery in bioprocessing investment. Strong proteins and analytics demand, improving orders and high-teens growth from emerging biotech customers suggest that recovery is broadening. Management raised its organic growth and earnings forecast, reinforcing Conestoga’s constructive outlook. Its planned acquisition of BioLife Solutions would add complementary biopreservation capabilities.
“improving order trends and high-teens growth from emerging biotechnology customers provided further evidence of a broader recovery in bioprocessing demand”
Key risks
- A renewed slowdown in biopharma orders and research funding could reverse the apparent demand recovery.
- Higher yields can compress premium valuations even for high-quality growth stocks.
- Integration of BioLife Solutions following the announced acquisition may create execution risk.